News about

(BMY) Bristol-Myers Squibb Company Earns Good News From FDA

Sat, 18 May 2013 12:00:32 -0400

Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug...

Visit StockBlogHub to view complete post.

Cheerleaders: Look Beyond Pharma For Jobs

Thu, 16 May 2013 17:05:16 -0400

Dividend Highlights/Lowlights for May 16

Thu, 16 May 2013 17:01:22 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Cisco Systems (CSCO) – up 13% Kohl’s Corporation (KSS) – up 5% Molson Coors (TAP) – up 3% Hewlett Packard (HPQ) – up 2% Icahn Enterprises L.P. (IEP) – up 2% Lowlights Computer Sciences (CSC) [...]

Busy Day For Bristol-Myers Options As Shares Sprint Higher

Wed, 15 May 2013 20:46:42 -0400

Today’s tickers: BMY, TIBX & WM

BMY - Bristol-Myers Squibb Co. – Shares in drug maker, Bristol-Myers Squibb Co., are ripping higher today, up 6.5% at $44.94, the highest level in more than a decade, ahead of the release of the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting abstracts tonight. The ASCO Annual Meeting begins on May 31st in Chicago. Options on BMY are far more active than usual today, with overall volume topping 64,000 contracts by 12:25 p.m. ET, versus average daily volume of around 11,400 contracts. Traders appear to be snapping up call options on the name, establishing near-term bullish positions on the stock to position for further gains in the price of the underlying. Front month calls are seeing most of the action, with intraday call volume well in excess of open interest across several striking prices. More than 7,000 calls have traded at the May $45 strike against open interest of 316 contracts, with roughly 3,600 calls purchased during the first half of the session for an average premium of $0.54 each. Call buyers make money if shares in BMY rally another 1.3% over the current level of $44.94 to settle above the average breakeven price of $45.54 by expiration this week. In and out of the money call options expiring June 21st are also seeing heavy volume in today’s session.

TIBX - TIBCO Software, Inc. – Upside call buying on software maker, TIBCO, suggests some traders are positioning for the price of the underlying to continue to gain ground in the near term. The stock is up 0.40% this morning at $20.91 as of 11:40 a.m. ET. Shares in TIBX, down roughly 30% since this time last year, have managed to rise 15% off a two-year low of $18.18 reached back on April 19th. Bullish options are changing hands at the Jun $20 strike today, with around 5,000 calls in play versus open interest of 2,742 contracts. Time and sales data indicates the bulk of the volume was purchased in the…

Dividend Highlights/Lowlights for May 15

Wed, 15 May 2013 16:57:56 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Bristol-Myers Squibb (BMY) – up 5% Eastman Chemical (EMN) – up 5% Agilent Technologies Inc. (A) – up 4% Family Dollar Stores (FDO) – up 3% Ford Motor Company (F) – up 3% Lowlights Computer [...]

Market Wrap for Wednesday, May 15: Bull Market Continues as Dow and S&P Hit New Highs

Wed, 15 May 2013 16:17:21 -0400

A late day push helped the U.S. stock market to another strong close on Wednesday. The Dow and S&P 500 finished the session at new all-time highs and all of the major averages recorded steady gains.

U.S. stocks have been on fire at the beginning of 2013 and the current

Closing Bell for Wednesday on Wall Street: Markets Open Soft, Close with a Flourish

Wed, 15 May 2013 12:04:00 -0400

DailyFinance.com: U.S. equity markets opened slightly lower this morning following a number of data releases related to the U.S. economy. Producer prices declined in April and the New York manufacturing index came in much lower than expected. U.S. industrial ... Read more

Amgen to Set Up JV in China – Analyst Blog

Tue, 14 May 2013 17:50:01 -0400

The JV, Amgen-Beta Pharmaceuticals Co., will focus on the commercialization of Amgen's colorectal cancer drug, Vectibix, in China.

(MRK) Merck & Company Joins Forces With Bristol-Myers Squibb on Hepatitis C Virus Candidates

Tue, 14 May 2013 13:40:36 -0400

Merck & Co. Inc. (MRK) recently joined forces with Bristol-Myers Squibb (BMY) to conduct a...

Visit StockBlogHub to view complete post.

Short Interest in Vertex Rises, in Celgene Falls

Sat, 11 May 2013 10:45:31 -0400

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April.

The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ:

Simcere Beats 1Q Earnings & Revenue Estimate – Analyst Blog

Fri, 10 May 2013 13:00:01 -0400

Simcere Pharmaceutical Group reported first quarter 2013 earnings of 9 cents per American Depositary Share (ADS) beating the Zacks Consensus Estimate by a penny.

“Marketing Without Innovation”: a Merck Story

Fri, 10 May 2013 11:42:16 -0400

Pharma’s Failure: Drug Spending Finally Declines

Thu, 09 May 2013 18:07:42 -0400

In Danish Laboratories, Hope Looms Large for a Permanent HIV Cure

Wed, 08 May 2013 14:42:00 -0400

Following successful in vitro studies, Danish researchers are on the fast track to human clinical trials.

Good News for Bristol-Myers – Analyst Blog

Mon, 06 May 2013 16:40:01 -0400

Bristol-Myers received positive news from the FDA when it approved Sustiva for treating children between three months and three years.

TD Ameritrade's IMX Survey Declines to 5.31 in April

Mon, 06 May 2013 13:50:48 -0400

TD Ameritrade (NYSE: AMTD) issued April data for the Investor Movement Index Monday afternoon. The survey, released monthly on either the first or second Monday of the month, is released at 12:30 PM Eastern.

The reading for April fell 0.06 from 5.37 in March to 5.31.

TD Ameritrade

(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate

Fri, 03 May 2013 13:49:09 -0400

Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate,...

Visit StockBlogHub to view complete post.

(MDCO) The Medicines Company Earnings Increase

Mon, 29 Apr 2013 16:47:46 -0400

The Medicines Company (MDCO) reported first quarter earnings of 24 cents per share, compared with...

Visit StockBlogHub to view complete post.

Market Wrap-Up for Apr.29 (AAPL, MCO, ETN, DIS, BMY, GE, more)

Mon, 29 Apr 2013 16:24:29 -0400

Another new week for the markets, and money continued to look for equities to remain in bullish territory. One thing we all know from the history of investor behavior is that higher prices tend to beget higher prices — until that simply stops working. Fundamentals aside, of course. Looking at today’s movers, Moody’s (MCO) was [...]

Merck Seeks Boost For $4B-a-Year Diabetes Drug

Mon, 29 Apr 2013 10:25:52 -0400

Leerink Swann Cuts Estimates on Bristol-Myers Squibb (BMY)

Mon, 29 Apr 2013 09:34:57 -0400

Due to lower sales of blood-clot and stroke drug Eliquis, analysts at Leerink Swann cut the earnings estimates of Bristol-Myers Squibb Company (BMY) through 2014 on Monday The analysts maintain a “Market Perform” rating on BMY. Bristol-Myers shares were up 4 cents, or +0.10%, during pre-market trading on Monday. The stock is up +23.14% year-to-date. [...]

A Look Ahead: This Week's ETFs to Watch

Sun, 28 Apr 2013 17:28:16 -0400

Last week was another fine one for U.S. stocks as the broader market fought off an array of data points that can only be considered mixed at best to again close higher. With last week's 1.4 percent pop, the S&P 500 is now up 0.8 percent this month and has

Earnings Increase at The Medicines Co. – Analyst Blog

Fri, 26 Apr 2013 17:30:01 -0400

First quarter 2013 revenues increased 23% year-over-year to $155.8 million, in-line with the Zacks Consensus Estimate.

Key Pfizer Drug in Trouble In Europe

Fri, 26 Apr 2013 14:11:03 -0400

Short Sellers Move into Celgene, Regeneron

Fri, 26 Apr 2013 13:25:43 -0400

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April.

The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ:

Company News for April 26, 2013 – Corporate Summary

Fri, 26 Apr 2013 10:36:01 -0400

Companies in the News are: BMY,D,CNX,CCE

Stocks Survive Once Again

Thu, 25 Apr 2013 18:15:00 -0400

Today's financial recap and tomorrow's financial outlook.

Dividend Highlights/Lowlights for April 25

Thu, 25 Apr 2013 16:48:08 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Dow Chemical (DOW) – up 6% Royal Caribbean Cruises Ltd. (RCL) – up 5% Las Vegas Sands (LVS) – up 4% American Tower Corp (AMT) – up 3.5% Foot Locker (FL) – up 3% Lowlights [...]

Bristol-Myers Reports In Line Earnings – Analyst Blog

Thu, 25 Apr 2013 11:53:01 -0400

Bristol-Myers' first quarter 2013 adjusted earnings were in line with the Zacks Consensus Estimate.

Bristol Myers Profit Declines on Expired Patents; Matches Earnings Estimates (BMY)

Thu, 25 Apr 2013 11:04:35 -0400

Biopharmaceutical company, Bristol Myers Squibb Co. (BMY) saw a decline in earnings on Thursday, caused by the loss of sales from expired patents. Still, the company matched analysts earnings estimates for the first quarter. The New York, NY based company reported first quarter earnings of $609 million, or 37 cents per share, down -45% from [...]

Stocks Market News for April 25, 2013 – Market News

Thu, 25 Apr 2013 10:36:01 -0400

A sharp fall in durable orders coupled with disappointing data from Procter & Gamble and AT&T dragged the Dow Jones into negative territory on Wednesday

Updates, advisories and surprises

Thu, 25 Apr 2013 10:31:09 -0400

A roundup of the latest corporate earnings reports and what companies are saying about future quarters.

Stock futures up ahead of Dow Chemical, claims

Thu, 25 Apr 2013 06:12:54 -0400

U.S. stock market futures rise ahead of Wall Street’s open on Thursday, against a backdrop of mixed global markets, as investors look ahead to earnings from Dow Chemical and Exxon Mobil and weekly jobless claims data.

Amazon, Starbucks, UPS are stocks to watch

Thu, 25 Apr 2013 05:30:46 -0400

Amazon.com, Starbucks, and United Parcel Service are among the stocks likely to be active on Thursday as the earnings parade continues.

Gilead Reports Encouraging HCV Data – Analyst Blog

Wed, 24 Apr 2013 19:40:01 -0400

Gilead announced detailed data on sofosbuvir

Another Reason the Pharma Pipeline is Lacking

Tue, 23 Apr 2013 12:09:44 -0400

Bristol-Myers Likely to Report In Line Earnings – Analyst Blog

Mon, 22 Apr 2013 17:15:01 -0400

We expect Bristol-Myers to report in line first-quarter 2013 results.

BMY, Santaris Pharma Team Up – Analyst Blog

Fri, 19 Apr 2013 17:10:01 -0400

Bristol-Myers recently entered into a strategic alliance with privately-held biopharmaceutical company Santaris Pharma A/S to discover and develop medicines on a global basis using latter's proprietary Locked Nucleic Acid (LNA) Drug Platform.

LabCorp Earnings Misses Again – Analyst Blog

Fri, 19 Apr 2013 11:26:01 -0400

LabCorp misses Zacks Consensus Estimate in the first quarter of 2013.

(GILD) Gilead Sciences Seeks FDA Approval

Thu, 18 Apr 2013 16:40:52 -0400

Gilead Sciences (GILD) recently submitted a New Drug Application (NDA) to the US Food and Drug...

Visit StockBlogHub to view complete post.

Positive Data on Lilly Diabetes Candidate – Analyst Blog

Thu, 18 Apr 2013 15:20:01 -0400

Results from the AWARD program will be used to support dulaglutide regulatory filings, which are scheduled for this year.

Merck’s $4 Billion Diabetes Drug in Trouble?

Thu, 18 Apr 2013 11:55:40 -0400

BMY to Expand Facility, Hire 350 – Analyst Blog

Fri, 12 Apr 2013 10:50:01 -0400

Bristol-Myers intends to expand its facility at Massachusetts.

Stock Market News for April 12, 2013 – Market News

Fri, 12 Apr 2013 10:36:01 -0400

Better-than-expected initial claims numbers lifted the major indices higher on Thursday

Bristol-Myers Squibb Expansion to Add 350 Jobs

Fri, 12 Apr 2013 03:07:00 -0400

DailyFinance.com: Getty Images NEW YORK -- Drugmaker Bristol-Myers Squibb plans to spend about $250 million expanding a manufacturing complex it opened in 2009 for biologic treatments. The New York company said Thursday that it will add two buildings to an 89-acre ... Read more

ETF Showdown: A Pharma Fight

Thu, 11 Apr 2013 16:21:34 -0400

Much has been made of low volatility sectors leading U.S. equities to new all-time highs. Sectors such as consumer staples and utilities are driving the broader market higher.

Health care is certainly in the conversation as well, and it is not just biotech names that are leading this sector's

Merck KGaA-CBRX Renew Agreement – Analyst Blog

Thu, 11 Apr 2013 16:00:01 -0400

Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years

Bristol-Myers to Expand Massachusetts Biologics Facility, to Invest $250M, Increase Workforce

Thu, 11 Apr 2013 10:17:22 -0400

Bristol-Myers Squibb (NYSE: BMY) today announced plans for an approximately $250 million expansion of its large-scale biologics manufacturing facility in Devens, Massachusetts. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.

“Biologics are increasingly important in the

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Wed, 10 Apr 2013 12:10:54 -0400

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick

Jefferies Raises Price Targets on Pharmaceutical Stocks (ABBV, ABT, BMY, more)

Wed, 10 Apr 2013 09:32:16 -0400

Jefferies analysts boosted the price target on a number of pharmaceutical companies on Wednesday, holding a positive view of the sector heading into earnings season. The analysts believe a number of the pharma stocks have attractive valuations, adding to the reasons for the bullish view on the sector. Price Target Increases AbbVie Inc. (ABBV) is [...]